CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 133 enrolled
Drug / intervention
Infliximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00749398
NCT00749398N/ACompleted
CompareCT.gov

Atlas of the Evolution of Psoriasis Lesions Under Remicade® : A Dynamic Standardized Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab

Merck Sharp & Dohme LLC·observational·Posted Sep 9, 2008·Updated Jul 28, 2015

In Brief

An observational study evaluating Infliximab for Psoriasis. Completed, enrolled 133 participants.

Detailed Summary

This is a national, multi-center, observational, prospective photographic atlas study in subjects who are treated with infliximab for moderate-to-severe psoriasis in daily clinic according to local country regulations and reimbursement.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 9, 2008
Enrollment StartSep 1, 2007
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.8 years ago

Interventions

Infliximabbiological

According to local country regulations.